The startup has developed a therapeutic platform that enhances respiratory care by softening inspiratory flow while maintaining expiratory positive airway pressure for patients initiating or struggling with positive airway pressure (PAP) therapy. This technology enables effective medication delivery for individuals with respiratory diseases, improving treatment adherence and health outcomes.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients initiating or struggling with Positive Airway Pressure (PAP) therapy often experience discomfort due to constant pressure, leading to poor adherence and ineffective treatment of respiratory conditions. Existing PAP devices may not adequately mimic natural breathing patterns, making therapy less tolerable.
Solution
SleepRes has developed KPAP™ (Kairos Positive Airway Pressure), a novel PAP therapy that enhances patient comfort by dynamically adjusting pressure levels during the respiratory cycle. KPAP™ lowers inspiratory pressure to more closely resemble natural breathing, while maintaining optimal expiratory pressure to ensure pharyngeal patency and lung volume. This approach optimizes pressure delivery, making PAP therapy more comfortable and tolerable for patients with Obstructive Sleep Apnea (OSA). Clinical trials have demonstrated that KPAP™ provides equivalent therapeutic efficacy to standard CPAP while significantly improving patient comfort.
Target Audience
The primary target audience includes individuals newly diagnosed with Obstructive Sleep Apnea (OSA) and current PAP users who struggle with adherence due to discomfort associated with traditional CPAP therapy.
Features
- KPAP™ algorithm: Dynamically adjusts inspiratory pressure, dropping it by 5cm H2O (2cm then 3cm) below therapeutic pressure to mimic natural breathing.
- Expiratory pressure modulation: Lowers pressure at the initiation of expiration, maintaining the reduction through most of the expiratory cycle.
- Therapeutic pressure restoration: Returns pressure to therapeutic levels at the end of expiration to ensure optimal pharyngeal patency and lung volume.
- Comfort-focused design: Preferred over CPAP by the vast majority of patients in comfort studies.
- Equivalent efficacy: Demonstrated equivalent AHI (Apnea-Hypopnea Index) reduction compared to standard CPAP in clinical trials.